Next-generation drug reduces endometrial cancer progression and death in trial
A new drug is effective at decreasing the recurrence of, and death from, endometrial cancer, an international study shows. The drug, called sacituzumab tirumotecan (sac-TMT), attaches to a protein on the surface of tumor cells and then delivers a targeted dose of a chemical that leads to cancer cell death.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Wireless neural chip tracks brain changes in real time after Alzheimer's drug administration
United Kingdom
-
Reproductive health and cystic fibrosis: New guidance offers options and hope
United Kingdom
-
Black patients can face longer breast cancer care delays, study finds
United Kingdom
-
AI-based computer model offers new weapon against hard-to-treat cancers
United Kingdom
-
AI could help identify people at higher risk of common cancers using routine health data
United Kingdom
-
Immunotherapy combination extends survival in advanced endometrial cancer
United Kingdom
-
Tiny Scottish Island’s Little Historical Society Makes Massive Discovery
United Kingdom
-
Young mothers see rapid increase in substance-related emergency department visits
United Kingdom